Beta Bionics (NASDAQ:BBNX) Price Target Raised to $28.00 at Truist Financial

Beta Bionics (NASDAQ:BBNX) had its price target increased by analysts at Truist Financial from $23.00 to $28.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price target suggests a potential upside of 28.85% from the company’s current price.

A number of other research firms also recently weighed in on BBNX. UBS Group restated a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a research note on Tuesday, September 15th. Bank of America increased their price objective on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Tuesday, September 15th. Wall Street Zen raised Beta Bionics from a “sell” rating to a “hold” rating in a report on Saturday, September 19th. Wells Fargo & Company started coverage on Beta Bionics in a research report on Wednesday. They issued an “overweight” rating and a $28.00 price target on the stock. Finally, Leerink Partners lifted their price objective on Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, September 14th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.91.

Beta Bionics Stock Performance

Shares of NASDAQ BBNX traded down $0.46 during mid-day trading on Thursday, reaching $21.73. The company had a trading volume of 243,052 shares, compared to its average volume of 1,187,138. The firm has a market cap of $977.63 million, a price-to-earnings ratio of -13.23 and a beta of 3.37. The business’s 50-day simple moving average is $17.98 and its 200 day simple moving average is $14.29. Beta Bionics has a one year low of $8.80 and a one year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The firm had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. On average, sell-side analysts anticipate that Beta Bionics will post -2.06 EPS for the current year.

Insider Buying and Selling

In related news, insider Mark Hopman sold 30,779 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27. Following the transaction, the insider owned 56,479 shares in the company, valued at $1,136,922.27. The trade was a 35.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mike Mensinger sold 2,650 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00. Following the completion of the sale, the insider owned 177,390 shares of the company’s stock, valued at $3,902,580. The trade was a 1.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 107,327 shares of company stock worth $2,070,421 over the last ninety days. 5.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Eventide Asset Management LLC grew its holdings in Beta Bionics by 0.8% during the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after buying an additional 37,476 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Beta Bionics in the second quarter valued at about $52,340,000. Eversept Partners LP raised its holdings in shares of Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after purchasing an additional 736,576 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Beta Bionics during the fourth quarter valued at about $40,437,000. Finally, Perceptive Advisors LLC grew its position in Beta Bionics by 39.8% in the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares in the last quarter.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Wells Fargo upgraded Beta Bionics to “strong-buy” and reportedly initiated coverage with an “overweight” rating and a $28 price target. The endorsement supports the bullish view that the company’s automated insulin-delivery products can gain market share. Wells Fargo upgrade
• Positive Sentiment: Beta Bionics announced an agreement with Senseonics to integrate its iLet Bionic Pancreas and mint systems with the Eversense 365 continuous glucose monitor. A combined system is expected to launch commercially in the fourth quarter of 2026, potentially expanding customer choice and strengthening BBNX’s competitive position in diabetes care. Beta Bionics and Senseonics partnership
• Neutral Sentiment: Analyst support remains generally favorable, with a consensus “Moderate Buy” rating and recent price-target increases. However, the company remains unprofitable, and its negative earnings and net margin limit the immediate fundamental support for the shares.
• Negative Sentiment: Several law firms are publicizing a securities-fraud class action against Beta Bionics. The case covers investors who purchased shares during periods in 2025 and early 2026, with a November 3, 2026 lead-plaintiff deadline. The repeated notices increase visibility around potential legal costs and reputational damage. Beta Bionics securities lawsuit
• Negative Sentiment: The allegations claim Beta Bionics inadequately disclosed FDA concerns, including a June 2025 Form 483 and more than 18,000 iLet-related complaints. The claims are unproven, but they create regulatory and product-safety uncertainty surrounding the company’s core device.
• Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her direct holdings by about 24.7%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which makes it a weaker discretionary bearish signal, but it may still weigh on sentiment. SEC insider transaction filing

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.